The Latest Cardiac and Vascular News
Phase 1 trial evaluated the pharmacokinetics and safety of HBI-3000 when dosed with thestrong CYP2D6 inhibitor, paroxetine SAN DIEGO, May 17, 2022 /PRNewswire/ — HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced the successful completion of a Phase 1 drug-drug interaction clinical trial of HBI-3000, a novel drug for cardioversion […]
AV-101 is being developed to address cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the pathophysiology of PAH PAH is an area of high unmet need, and currently approved therapies are limited by acting primarily through vasodilation These Phase 1 results show that […]
IRVINE, Calif., May 17, 2022 (GLOBE NEWSWIRE) — JenaValve Technology, Inc. (“JenaValve or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the appointment of Kari Moore as the Company’s CFO effective May 10th, 2022. “We are excited to welcome Kari to the JenaValve […]
FDA Plans to Convene Advisory Committee Meeting SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the Company recently participated in a mid-cycle communication meeting with the U.S. Food & Drug Administration (FDA) and was informed that the Agency plans to convene an […]
Funds will support clinical development and regulatory approval of fully absorbable percutaneous closure devices for large-bore vessels GALWAY, Ireland–(BUSINESS WIRE)–Vivasure Medical® (“Vivasure” or the “Company”), a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the closing of the first tranche of €22 million ($23M) as part of […]
Conference call begins at 4:30 p.m. Eastern time today CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or “the Company”), a medical device company focusing on developing its excimer laser system to treat vascular disease, reports financial results for the three months ended March 31, 2022 and […]
Company to focus on improving the quality of care for all cardiovascular patients in the U.S. ALISO VIEJO, Calif.–(BUSINESS WIRE)–On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the American College of Cardiology (JACC), egnite, Inc. today announced that it has expanded the company’s focus […]
Pulse Technologies’ HSR™ electrode surface treatment is now part of Cardionomic’s Cardiac Pulmonary Nerve Stimulation (CPNS) System for treating heart failure. QUAKERTOWN, Pa., May 16, 2022 /PRNewswire/ — Pulse Technologies Inc. has announced that its proprietary Hierarchical Surface Restructuring (HSR™) technology is being utilized as part of Cardionomic’s Cardiac Pulmonary Nerve Stimulation […]
LONDON, May 16, 2022 /PRNewswire/ — Tamer, the Middle-East’s leading healthcare distribution company, has agreed a 5-year deal to bring Huma’s market leading technology platform to power ‘hospitals at home’ with remote patient monitoring to the 34 million people living in the Kingdom of Saudi Arabia. The new health programme will begin with support for […]
WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended March 31, 2022, and recent business highlights. Recent Highlights Reiterating strong […]
